LBA79 - Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Background

The coronavirus disease 2019 (COVID-19) pandemic is having significant impact on oncological care (Joode et al, Eur J Cancer 2020;136:132-139) and patients with cancer might have an increased risk for severe outcome of COVID-19. In order to identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19.

Methods

This ongoing multicentre nationwide observational cohort study was designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a collaboration of oncology physicians in the Netherlands. A questionnaire was developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis, cancer treatment, and outcome of COVID-19. All patients with COVID-19 and a cancer diagnosis or cancer treatment in the past 5 years were eligible for inclusion.

Results

To date, > 600 cancer patients diagnosed with COVID-19 have been registered by 45 Dutch hospitals. Data of 442 registered patients with at least 4 weeks follow-up were cleaned and 351 patients could be included for the first analyses. The main cancer diagnoses were non-small cell lung cancer (13.4%), breast cancer (13.4%), and chronic lymphocytic leukaemia (8.8%). Overall, 114 (32.3%) out of 351 patients with cancer died from COVID-19. In multivariate analyses, age ≥ 65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045), and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥ 65 years).

Conclusions

The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to SARS-CoV-2, whereas treatment adjustments and prioritizing vaccination, when available, should also be considered.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Erasmus Medical Center.

Funding

Dutch Cancer Society.

Disclosure

D.W. Dumoulin: Honoraria (self), Speakers fee: MSD; Honoraria (self), Speakers fee : Roche; Honoraria (self), Speakers fee: Astazeneca; Honoraria (self), Speakers fee: BMS; Honoraria (self), Speakers fee: Novartis; Honoraria (self), Speakers fee: Pfizer. H.M. Westgeest: Honoraria (self): Astellas; Honoraria (self): Roche; Travel/Accommodation/Expenses: Ipsen. L.E.L. Hendriks: Advisory/Consultancy, Mentorship program with key opinion leaders: funded by AstraZeneca: AstraZeneca; Honoraria (self), Educational webinars: Quadia; Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Paid to institution: Eli Lilly; Advisory/Consultancy, Paid to institution: Roche Genentech; Advisory/Consultancy, Paid to institution: Pfizer; Advisory/Consultancy, Advisory board and speakers fee all paid to institution: MSD; Advisory/Consultancy, Paid to institution: Takeda; Leadership role, Local PI of pharma initiated research: AstraZeneca; Leadership role, Local PI of pharma initiated research: Novartis; Leadership role, Local PI of pharma initiated research: BMS; Leadership role, Local PI of pharma initiated research: MSD / Merck; Leadership role, Local PI of pharma initiated research: GSK; Leadership role, Local PI of pharma initiated research: Takeda; Leadership role, Local PI of pharma initiated research: Blueprint Medicines; Leadership role, Local PI of pharma initiated research: Roche Genentech; Advisory/Consultancy, Paid to institution: Amgen; Advisory/Consultancy, Paid to institution: Boehringer Ingelheim; Advisory/Consultancy, Paid to institution: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses, Advisory board paid to institution: Roche Genentech; Travel/Accommodation/Expenses: BMS; Research grant/Funding (institution): Roche Genentech; Research grant/Funding (institution): Boehringer Ingelheim. A-M.C. Dingemans: Honoraria (self): Roche; Honoraria (self): Eli Lilly; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Takeda; Honoraria (self): PharmaMar; Advisory/Consultancy, non financial support: AbbVie; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Amgen. A.A.M. Van der Veldt: Honoraria (institution), Advisory/Consultancy: BMS; Honoraria (institution), Advisory/Consultancy: MSD; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: Eisai; Honoraria (institution), Advisory/Consultancy: Ipsen; Honoraria (institution), Advisory/Consultancy: Roche; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: Merck; Honoraria (institution), Advisory/Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.